Nottingham, 20 October 2025
Upperton Pharma Solutions announces its recognition as winner of the Small Molecule Dosage Form category at the inaugural European CDMO Leadership Awards, held on October 28th, alongside being named a Champion finalist. This recognition marks a major milestone in Upperton’s growth as a leading contract development and manufacturing organization (CDMO).
The CDMO Leadership Awards Europe are unique because winners are based on customer feedback. The awards reflect the views of the biopharma companies who rely on CDMOs to bring their products to life. As Louis Garguilo, Chief Editor of Outsourced Pharma, explains:
“The 2025 CDMO Leadership Awards Europe is a well-deserved recognition to European organizations that have demonstrated excellence in contract development and manufacturing. These awards are the most important in our industry because they are based on the judgement of biopharma sponsors and the value they place in trusted partnerships.”
For Upperton, this award is a reflection of the trust and respect earned from clients across Europe. It validates our strategic focus on small molecule dosage forms and our dedication to supporting small and medium-sized biotech companies with development and manufacturing across oral, nasal, pulmonary and sterile dosage forms.
This win follows our recent success at the Pharma Industry Awards UK, where Upperton was selected as Contract Services Company of the Year. Together, these accolades highlight our growing reputation across the European market and the increasing importance of CDMOs that can guide clients from preclinical through to market success.
Upperton CEO, Nikki Whitfield, shared her thoughts on the significance of this award:
“Recognition at awards is always special, but to have this one voted on by our own customers in the industry is a real recognition of the industry respect we’ve gathered from clients.”
Why Small Molecule Matters
Small molecule drugs remain a cornerstone of modern medicine, but developing and manufacturing them demands deep technical expertise, from formulation and scalability to regulatory compliance.
Upperton has long specialised in oral and nasal dosage forms, providing end-to-end support from early-stage development through clinical and commercial manufacturing. Our team combines scientific rigor with collaboration to ensure every project is delivered with precision and care.
Winning in the Small Molecule Dosage Form category is a testament to our technical excellence and ability to turn complex science into practical solutions. It also reflects our ongoing investment in state-of-the-art facilities, including our new sterile manufacturing facility, which further expands our capabilities and supports our clients’ continued growth.
–ENDS-
Notes to editors:
About Upperton Pharma Solutions:
Upperton has over 25 years’ experience of delivering science-led, high quality, innovative drug development and manufacturing solutions to pharmaceutical and biotechnology clients worldwide.
Based in Nottingham, UK, Upperton has a 60,000 sq. ft development and manufacturing facility, with formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing and quality control testing capability. Upperton is MHRA Approved to manufacture materials for clinical trial supplies. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which addresses both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products.
The company employs over one hundred highly skilled personnel and has its headquarters in Nottingham, UK.
For further information, images, and interview opportunities, please contact:
Rob Halliwell, Associate Director of Marketing, Upperton
rob.halliwell@upperton.com
upperton.com